Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04499833

HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma

Liver transplant is the most effective treatment for hepatocellular carcinoma (HCC) in cirrhosis. Due to organs shortage, the proper selection of patients is imperative. Prevailing clinical morphological models used in most centres (Milan Criteria), can exclude potential candidates and include patients with aggressive biological behaviour. To more accurately select candidates for liver transplant, the inclusion of criteria that could predict the behaviour and aggressiveness of tumours, such as molecular markers, might be useful.

The investigators propose the use of a new algorithm (HepatoPredict Prognostic Tool), that combine clinical and molecular criteria that address the biology of tumours, in a single centre prospective, intervention study. Data from the "HepatoPredict genomic signature" are added to the clinical and imagiology algorithm. Based on this tool, patients outside the usual eligibility criteria for liver transplant will be proposed for this treatment. These patients will be transplanted with marginal livers or with livers from patients with Familial Amyloid Polyneuropathy, not competing with patients on the waiting list. Patients will be followed up to 60 months after transplant, to assess survival and HCC recurrence with biannual imagiology screening. Survival and disease-free-survival rates will be compared with those obtained by the usual management of patients included and excluded by Milan Criteria.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centro Hepato-bilio-pancreático e de Transplantação do Hospital Curry Cabral

Lisbon, 1069-166, Portugal

Location status: Recruiting

Location contact

Hugo Pinto-Marques, MD PhD

CONTACT

[email protected]

+351917302214

Jose Pereira-Leal, PhD

SUB_INVESTIGATOR

Luis Pereira-de-Silva, MD PhD

CONTACT

[email protected]

+351213596402 ext. 51402

Sílvia Gomes-da-Silva, MD

SUB_INVESTIGATOR

About this study

Liver transplant is the most effective treatment for hepatocellular carcinoma (HCC) in cirrhosis. Due to organs shortage, the proper selection of patients is imperative. Prevailing clinical morphological models used in most centres (Milan Criteria), can exclude potential candidates and include patients with aggressive biological behaviour. To more accurately select candidates for liver transplant, the inclusion of criteria that could predict the behaviour and aggressiveness of tumours, such as molecular markers, might be useful. The investigators propose the use of a new algorithm (HepatoPredict Prognostic Tool, Ophiomics), combining morphologic information, clinical and molecular criteria, in a prospective, intervention, single centre study.

Patients aged 18 to 70 years, with HCC in cirrhosis, not eligible for liver transplant under the "Milan Criteria", whom had the following morphologic characteristics: total tumour volume below 500 cm3, total number of tumour lesions below 10 and maximum individual tumour diameter below 10 cm, will be proposed for the "HepatoPredict genomic signature" analysis (Ophiomics), obtained from DNA of tumor samples. Those considered candidates by the algorithm are to be proposed for transplant with marginal livers or with livers from patients with Familial Amyloid Polyneuropathy.

Patients will be followed up to 60 months after transplant, to assess survival and HCC recurrence with biannual imagiology screening by triphasic CT scan. Additionally, circulating tumour DNA will be assessed previously to the transplant and biannually for up to 60 months. Survival and disease-free-survival rates will be compared with those obtained with the usual management of patients included and excluded by Milan Criteria, both in the same referral transplant center and in the published literature.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hepatocellular carcinoma associated with cirrhosis
  • Ages between 18 and 70 years
  • Total tumour volume below 500 cm3
  • Total number of tumour lesions below 10
  • Maximum individual tumour diameter below 10 cm

Exclusion criteria

  • eligible under the "Milan Criteria"

Treatment and study plan

Liver transplant

Procedure

liver transplant

Primary outcomes

  1. death

    Time frame: from 6 months after liver transplant up to 60 months

    death by any cause

  2. hepatocellular carcinoma recurrence

    Time frame: from 6 months after liver transplant up to 60 months

    identification of hepatocellular carcinoma recurrence through biannual triphasic CT scan

Secondary outcomes

  1. hepatocellular carcinoma recurrence through liquid biopsy

    Time frame: from 6 months after liver transplant up to 60 months

    early identification of hepatocellular carcinoma DNA through biannual serum samples (liquid biopsy)

Study contacts

Contact information is provided by the study sponsor or research team.

Hugo Pinto-Marques, MD PhD

CONTACT

[email protected]

+351917302214

Sílvia Gomes-da-Silva, MD

CONTACT

[email protected]

+351916876393

Sponsors and collaborators

Lead sponsor

Centro Hospitalar de Lisboa Central

Other

Collaborators

  • Ophiomics - Precision Medicine

Registry information

Official study title

Evaluation of the HepatoPredict Prognostic Tool in the Decision of Liver Transplant in Hepatocellular Carcinoma

Acronym: HepatoPredict

Important dates

Study start
2021
Primary completion
2028
Study completion
2029
First posted
Aug 5, 2020
Registry last updated
Jun 6, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.